Literature DB >> 22113611

Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.

Philipp Koch1, Peter Breuer, Michael Peitz, Johannes Jungverdorben, Jaideep Kesavan, Daniel Poppe, Jonas Doerr, Julia Ladewig, Jerome Mertens, Thomas Tüting, Per Hoffmann, Thomas Klockgether, Bernd O Evert, Ullrich Wüllner, Oliver Brüstle.   

Abstract

Machado-Joseph disease (MJD; also called spinocerebellar ataxia type 3) is a dominantly inherited late-onset neurodegenerative disorder caused by expansion of polyglutamine (polyQ)-encoding CAG repeats in the MJD1 gene (also known as ATXN3). Proteolytic liberation of highly aggregation-prone polyQ fragments from the protective sequence of the MJD1 gene product ataxin 3 (ATXN3) has been proposed to trigger the formation of ATXN3-containing aggregates, the neuropathological hallmark of MJD. ATXN3 fragments are detected in brain tissue of MJD patients and transgenic mice expressing mutant human ATXN3(Q71), and their amount increases with disease severity, supporting a relationship between ATXN3 processing and disease progression. The formation of early aggregation intermediates is thought to have a critical role in disease initiation, but the precise pathogenic mechanism operating in MJD has remained elusive. Here we show that L-glutamate-induced excitation of patient-specific induced pluripotent stem cell (iPSC)-derived neurons initiates Ca(2+)-dependent proteolysis of ATXN3 followed by the formation of SDS-insoluble aggregates. This phenotype could be abolished by calpain inhibition, confirming a key role of this protease in ATXN3 aggregation. Aggregate formation was further dependent on functional Na(+) and K(+) channels as well as ionotropic and voltage-gated Ca(2+) channels, and was not observed in iPSCs, fibroblasts or glia, thereby providing an explanation for the neuron-specific phenotype of this disease. Our data illustrate that iPSCs enable the study of aberrant protein processing associated with late-onset neurodegenerative disorders in patient-specific neurons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22113611     DOI: 10.1038/nature10671

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  25 in total

Review 1.  Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts?

Authors:  D C Rubinsztein; A Wyttenbach; J Rankin
Journal:  J Med Genet       Date:  1999-04       Impact factor: 6.318

2.  Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo.

Authors:  H Ikeda; M Yamaguchi; S Sugai; Y Aze; S Narumiya; A Kakizuka
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

Review 3.  Neuronal calcium signaling.

Authors:  M J Berridge
Journal:  Neuron       Date:  1998-07       Impact factor: 17.173

4.  Non-expanded polyglutamine proteins in intranuclear inclusions of hereditary ataxias--triple-labeling immunofluorescence study.

Authors:  T Uchihara; H Fujigasaki; S Koyano; A Nakamura; S Yagishita; K Iwabuchi
Journal:  Acta Neuropathol       Date:  2001-08       Impact factor: 17.088

5.  Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy.

Authors:  Mei Li; Erica S Chevalier-Larsen; Diane E Merry; Marc I Diamond
Journal:  J Biol Chem       Date:  2006-11-22       Impact factor: 5.157

6.  Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo.

Authors:  E Scherzinger; R Lurz; M Turmaine; L Mangiarini; B Hollenbach; R Hasenbank; G P Bates; S W Davies; H Lehrach; E E Wanker
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

7.  Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.

Authors:  Sarah J Shoesmith Berke; Francisca A Flores Schmied; Ewout R Brunt; Lisa M Ellerby; Henry L Paulson
Journal:  J Neurochem       Date:  2004-05       Impact factor: 5.372

8.  In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis.

Authors:  Aislinn J Williams; Tina M Knutson; Veronica F Colomer Gould; Henry L Paulson
Journal:  Neurobiol Dis       Date:  2008-11-08       Impact factor: 5.996

9.  A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration.

Authors:  Kei Watase; Edwin J Weeber; Bisong Xu; Barbara Antalffy; Lisa Yuva-Paylor; Kouichi Hashimoto; Masanobu Kano; Richard Atkinson; Yaling Sun; Dawna L Armstrong; J David Sweatt; Harry T Orr; Richard Paylor; Huda Y Zoghbi
Journal:  Neuron       Date:  2002-06-13       Impact factor: 17.173

Review 10.  Polyglutamine neurodegeneration: protein misfolding revisited.

Authors:  Aislinn J Williams; Henry L Paulson
Journal:  Trends Neurosci       Date:  2008-09-06       Impact factor: 13.837

View more
  139 in total

1.  Stem cells: The cell division.

Authors:  Alison Abbott
Journal:  Nature       Date:  2011-12-15       Impact factor: 49.962

2.  Evolution of iPSC disease models.

Authors:  Weiqi Zhang; Zhichao Ding; Guang-Hui Liu
Journal:  Protein Cell       Date:  2012-01       Impact factor: 14.870

3.  Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes.

Authors:  P Conforti; D Besusso; V D Bocchi; A Faedo; E Cesana; G Rossetti; V Ranzani; C N Svendsen; L M Thompson; M Toselli; G Biella; M Pagani; E Cattaneo
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

Review 4.  Clinical neurogenetics: autosomal dominant spinocerebellar ataxia.

Authors:  Vikram G Shakkottai; Brent L Fogel
Journal:  Neurol Clin       Date:  2013-07-30       Impact factor: 3.806

Review 5.  Induced neural stem cells (iNSCs) in neurodegenerative diseases.

Authors:  Andreas Hermann; Alexander Storch
Journal:  J Neural Transm (Vienna)       Date:  2013-05-30       Impact factor: 3.575

Review 6.  Induced pluripotent stem cells: the new patient?

Authors:  Milena Bellin; Maria C Marchetto; Fred H Gage; Christine L Mummery
Journal:  Nat Rev Mol Cell Biol       Date:  2012-10-04       Impact factor: 94.444

7.  Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line.

Authors:  Lauren R Moore; Laura Keller; David D Bushart; Rodrigo G Delatorre; Duojia Li; Hayley S McLoughlin; Maria do Carmo Costa; Vikram G Shakkottai; Gary D Smith; Henry L Paulson
Journal:  Stem Cell Res       Date:  2019-07-16       Impact factor: 2.020

Review 8.  Epigenetics of reprogramming to induced pluripotency.

Authors:  Bernadett Papp; Kathrin Plath
Journal:  Cell       Date:  2013-03-14       Impact factor: 41.582

9.  Physiological and pathophysiological characteristics of ataxin-3 isoforms.

Authors:  Daniel Weishäupl; Juliane Schneider; Barbara Peixoto Pinheiro; Corinna Ruess; Sandra Maria Dold; Felix von Zweydorf; Christian Johannes Gloeckner; Jana Schmidt; Olaf Riess; Thorsten Schmidt
Journal:  J Biol Chem       Date:  2018-11-19       Impact factor: 5.157

Review 10.  Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience.

Authors:  Jerome Mertens; Maria C Marchetto; Cedric Bardy; Fred H Gage
Journal:  Nat Rev Neurosci       Date:  2016-05-19       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.